Results 31 to 40 of about 34,512 (245)

Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism

Frontiers in Endocrinology, 2020
Aim: Isocitrate dehydrogenase 1 (IDH1) is key enzyme involved in cellular metabolism and DNA repair. Mutations in IDH1 occur in up to 25% of cholangiocarcinomas.
Li Su, Xinglong Zhang, Lei Zheng, Miaomiao Wang, Zhifa Zhu, Ping Li   +5 more
doaj   +1 more source

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia [PDF]

Frontiers in Oncology, 2021
Recently, the discovery of biological and clinical properties of mutated isoforms 1 and 2 mutations of isocitrate dehydrogenases (IDH) 1 and 2, affecting approximately 20% of patients with acute myeloid leukemia (AML), lead to the development of an individualized treatment strategy.
Cerchione, Claudio, Romano, Alessandra, Daver, Naval, DiNardo, Courtney, Jabbour, Elias Joseph, Konopleva, Marina, Ravandi-Kashani, Farhad, Kadia, Tapan, Martelli, Maria Paola, Isidori, Alessandro, Martinelli, Giovanni, Kantarjian, Hagop   +11 more
openaire   +5 more sources

Vitamin C in combination with inhibition of mutant IDH1 synergistically activates TET enzymes and epigenetically modulates gene silencing in colon cancer cells

Epigenetics, 2020
Mutations in the enzyme isocitrate dehydrogenase 1 (IDH1) lead to metabolic alterations and a sustained formation of 2-hydroxyglutarate (2-HG). 2-HG is an oncometabolite as it inhibits the activity of α-ketoglutarate-dependent dioxygenases such as ten ...
Christian Gerecke, Fabian Schumacher, Alide Berndzen, Thomas Homann, Burkhard Kleuser   +4 more
doaj   +1 more source

IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced. [PDF]

PLoS ONE, 2017
Mutations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) gene were recently discovered in vast majority of World Health Organization (WHO) grade II/III gliomas.
Huixia Zhu, Ye Zhang, Jianfeng Chen, Jiangdong Qiu, Keting Huang, Mindan Wu, Chunlin Xia   +6 more
doaj   +1 more source

TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms

Turkish Journal of Hematology, 2017
We aimed to determine the genotype distribution, allele frequency, and prognostic impact of IDH1/2, TET2, and ASXL1 single nucleotide polymorphisms (SNPs) in myeloproliferative neoplasms (MPNs).
Nur Soyer, Burçin Tezcanlı Kaymaz, Melda Cömert Özkan, Çağdaş Aktan, Ali Şahin Küçükaslan, Fahri Şahin, Buket Kosova, Güray Saydam   +7 more
doaj   +1 more source

Single-center, observational study of AML/MDS-EB with IDH1/2 mutations: genetic profile, immunophenotypes, mutational kinetics and outcomes

Hematology, 2023
Objective IDH1/2 mutations, intervening in epigenetic procedures, are frequently encountered in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Vasiliki Papadopoulou, Jacqueline Schoumans, Valentin Basset, Françoise Solly, Jérôme Pasquier, Sabine Blum, Olivier Spertini   +6 more
doaj   +1 more source

Immunohistochemical Expression of IDH1, ATRX, Ki67, GFAP, and Prognosis in Indonesian Glioma Patients

International Journal of General Medicine, 2023
Dody Priambada,1 Muhamad Thohar Arifin,1 Abdi Saputro,1 Azka Muzakka,1 Vega Karlowee,2 Udadi Sadhana,2 Yuriz Bakhtiar,1 Krisna Tsaniadi Prihastomo,1 Ajid Risdianto,1 Happy Kurnia Brotoarianto,1 Erie Andar,1 Zainal Muttaqin1 1Department of Neurosurgery ...
Priambada D, Thohar Arifin M, Saputro A, Muzakka A, Karlowee V, Sadhana U, Bakhtiar Y, Prihastomo KT, Risdianto A, Brotoarianto HK, Andar E, Muttaqin Z   +11 more
doaj  

The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET

BMC Cancer, 2021
Background Non-invasive diagnosis of IDH1 mutation for gliomas has great clinical significance, and PET has natural advantage to detect metabolism, as IDH mutated gliomas share lower glucose consumption. Methods Clinical data of patients with gliomas and
Feng-Min Liu, Yu-fei Gao, Yanyan Kong, Yihui Guan, Jinsen Zhang, Shuai-Hong Li, Dan Ye, Wenyu Wen, Chuantao Zuo, Wei Hua   +9 more
doaj   +1 more source

Favorable role of IDH1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma

Future Science OA, 2021
Aim: The implications of molecular biomarkers IDH1/2 mutations and MGMT gene promoter methylation were evaluated for prognostic outcome of glioma patients. Materials & methods: Glioma cases were analyzed for IDH1/2 mutations and MGMT promoter methylation
Arshad A Pandith, Iqbal Qasim, Shahid M Baba, Aabid Koul, Wani Zahoor, Dil Afroze, Adil Lateef, Usma Manzoor, Ina A Bhat, Dheera Sanadhya, Abdul R Bhat, Altaf U Ramzan, Fozia Mohammad, Iqra Anwar   +13 more
doaj   +1 more source

NRF2 signalling in cytoprotection and metabolism

British Journal of Pharmacology, EarlyView., 2023
The KEAP1‐NRF2 system plays a central role in cytoprotection in defence mechanisms against oxidative stress. The KEAP1‐NRF2 system has been regarded as a sulfur‐utilizing cytoprotective mechanism, because KEAP1 serves as a biosensor for electrophiles by using its reactive thiols and NRF2 is a transcriptional factor regulating genes involved in sulfur ...
Shohei Murakami, Yusuke Kusano, Keito Okazaki, Takaaki Akaike, Hozumi Motohashi   +4 more
wiley   +1 more source